Atea Pharmaceuticals
AVIR
103 hedge funds and large institutions have $1.26B invested in Atea Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 42 increasing their positions, 17 reducing their positions, and 17 closing their positions.
147% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 17
129% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 17
27% more funds holding
Funds holding: 81 → 103 (+22)
11.35% more ownership
Funds ownership: 59.84% → 71.18% (+11%)
21% less call options, than puts
Call options by funds: $3.75M | Put options by funds: $4.77M
44% less funds holding in top 10
Funds holding in top 10: 9 → 5 (-4)
58% less capital invested
Capital invested by funds: $3.04B → $1.26B (-$1.78B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$103M |
| 2 |
BlackRock
New York
|
+$72.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$49.6M |
| 4 |
AICPI
ABG Innovation Capital Partners III
Central, Hong Kong,
Hong Kong
|
+$38M |
| 5 |
Morgan Stanley
New York
|
+$22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCPEMI
Bain Capital Public Equity Management II
Boston,
Massachusetts
|
-$52.3M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$27.7M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$27.2M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$26.1M |
| 5 |
PA
Perceptive Advisors
New York
|
-$25.5M |
AVIR Hedge Fund Activity: Q2 2021 in Review
103 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q2 2021, worth a combined $1.26B — down 58% from $3.04B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new AVIR positions and 17 closed out — a net gain of 22 holders — while 42 added to existing stakes and 17 trimmed.
The largest buyer was Vanguard Group, adding an estimated $103M. The largest seller was Bain Capital Public Equity Management II, exiting entirely with an estimated $52.3M sold.
- 103 institutional investors held Atea Pharmaceuticals (AVIR) as of Q2 2021, up from 81 in Q1 2021.
- Funds reported $1.26B of Atea Pharmaceuticals stock for Q2 2021, down 58% quarter-over-quarter.
- 39 funds opened new Atea Pharmaceuticals positions in Q2 2021 and 17 closed out, a net change of +22 holders.
- The largest Atea Pharmaceuticals buyer in Q2 2021 was Vanguard Group, an estimated $103M added.
- The largest Atea Pharmaceuticals seller in Q2 2021 was Bain Capital Public Equity Management II, an estimated $52.3M sold.
Based on aggregated 13F filings for Q2 2021.